Additionally, multivariate analysis demonstrated that ITGA5 expression in primary breast tumors is an independent prognostic factor for bone relapse; their study identifies ITGA5 as a contributor to breast cancer metastasis to bone and suggests that volociximab/M200 might be repurposed for treating breast cancer patients with bone metastases who are ITGA5‐positive [65]. Here, ITGA5 is linked to breast carcinoma.